LAG-3
37 programs · 34 companies
Programs
37
Companies
34
Active Trials
30
Targeting LAG-3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | MigraineMM | |
| Polazasiran | Amgen | Phase 2 | MM | |
| ALN-6288 | Alnylam | Approved | DravetRB | |
| Sovarelsin | Alnylam | Phase 2/3 | MCLCSU | |
| STO-2663 | Stoke Ther | Approved | CholangiocarcinomaPTSD | |
| CVA-2171 | CureVac | Phase 1/2 | ADHDParkinson's | |
| CSL-2468 | CSL Limited | Phase 1/2 | HNSCCPAH | |
| 451-2703 | Chugai | Phase 1 | Crohn'sHNSCC | |
| 450-3790 | Sumitomo Pharma | Preclinical | T2D | |
| DAN-IIT-542 | Dana-Farber | Phase 2 | Fabry | |
| CHI-IIT-214 | Children's Oncology Grp | Phase 3 | Atopic Derm | |
| FRE-IIT-644 | Fred Hutch Cancer Ctr | Phase 3 | PTSD | |
| UCS-IIT-166 | UCSF | Phase 1 | HNSCC | |
| UCS-IIT-914 | UCSF | Approved | Alzheimer's | |
| UCS-IIT-264 | UCSF | Phase 3 | CF | |
| Polamavacamten | Emergent Bio | Phase 2 | Endometrial CaMeso | |
| ALD-5252 | Aldeyra Ther | Phase 2/3 | SchizophreniaMM | |
| Datoderotide | CytoDyn | Phase 3 | RANASH | |
| HRT-9539 | Heron Therapeutics | NDA/BLA | Wet AMD | |
| TAR-8916 | Taro Pharma | Phase 1 | SCD | |
| 086-8509 | Medytox | Phase 2/3 | GBMMG | |
| OCU-3469 | Ocuphire | Phase 1 | NBOvarian Ca | |
| Sotolucimab | StrideBio | Phase 2/3 | PV | |
| ORC-2834 | Orchard (Kyowa) | Phase 2/3 | GBMOvarian Ca | |
| SEN-3594 | Sensei Bio | Phase 2/3 | CMLCTCL | |
| Doxafotisoran | Daiichi Sankyo EU | Phase 3 | AS | |
| Lisosacituzumab | Curocell | Phase 1/2 | PompeFTD | |
| 219-3907 | Clover Bio | Approved | ThymomaPV | |
| ADP-7169 | Adaptive Biotechnologies | Approved | Atopic Derm | |
| Zanutinib | Newron Pharma | Approved | ADHDWet AMD | |
| SMM-5951 | Summit Therapeutics | Phase 2/3 | AngelmanRCC | |
| CHI-IIT-303 | Chinese PLA General Hosp | Phase 2/3 | TTR Amyloidosis | |
| HOS-IIT-591 | Hospital Israelita Einstein | Phase 3 | Heart Failure | |
| KIN-IIT-616 | King Faisal Spec Hosp | Phase 2 | Pancreatic Ca | |
| 002-1797 | Shanghai RAAS | Approved | Huntington's | |
| 600-5291 | Zhejiang Medicine | Phase 2 | OCDParkinson's | |
| WAT-3378 | Waters Corp | Phase 2 | CKD |